Scarica l'app Stockscreener
23.65
2.83%
0.65
Pre-mercato:
23.65
Precedente Chiudi:
$23.00
Aprire:
$23.02
Volume 24 ore:
1.32M
Relative Volume:
0.84
Capitalizzazione di mercato:
$1.44B
Reddito:
-
Utile/perdita netta:
$-107.85M
Rapporto P/E:
-10.70
EPS:
-2.21
Flusso di cassa netto:
$-106.82M
1 W Prestazione:
+1.46%
1M Prestazione:
-25.49%
6M Prestazione:
-43.96%
1 anno Prestazione:
-32.29%
Intervallo 1D:
$22.75
$23.77
Intervallo di 1 settimana:
$22.28
$25.30
Portata 52W:
$18.53
$51.61
Vera Therapeutics Inc Stock (VERA) Company Profile
Nome
Vera Therapeutics Inc
Settore
Industria
Telefono
650-770-0077
Indirizzo
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Confronta VERA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
23.65 | 1.44B | 0 | -107.85M | -106.82M | -2.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-05 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2025-01-28 | Iniziato | Goldman | Buy |
| 2024-11-21 | Iniziato | Wells Fargo | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-01-25 | Iniziato | Oppenheimer | Outperform |
| 2024-01-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-12-18 | Iniziato | Raymond James | Outperform |
| 2023-11-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-16 | Iniziato | Guggenheim | Buy |
| 2023-01-04 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-04 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-07-12 | Iniziato | JP Morgan | Overweight |
| 2022-05-02 | Iniziato | H.C. Wainwright | Buy |
| 2022-04-19 | Iniziato | Wedbush | Outperform |
Mostra tutto
Vera Therapeutics Inc Borsa (VERA) Ultime notizie
Vera Therapeutics Inc put volume heavy and directionally bearish - TipRanks
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - Investing.com
Transcript : Vera Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 03 - marketscreener.com
Vera Therapeutics (VERA) Sees Surge in Bullish Options Activity | VERA Stock News - GuruFocus
Vera Therapeutics reports inducement grants under Nasdaq listing rule - MarketScreener
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera Therapeutics Expands Team with 17 New Hires, Awards Major Stock Options Worth $6M - Stock Titan
H.C. Wainwright maintains $85 target on Vera Therapeutics stock By Investing.com - Investing.com Canada
Wedbush Cuts Price Target on Vera Therapeutics to $23 From $32, Keeps Neutral Rating - marketscreener.com
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by Wellington Management Group LLP - Defense World
California State Teachers Retirement System Acquires 6,749 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics (NASDAQ:VERA) Shares Gap Down – Should You Sell? - Defense World
Biotech Stocks To Watch Today – June 6th - Defense World
Otsuka’s IgAN Data Top Some Vera Results, But To What End? - insights.citeline.com
Vera Therapeutics (VERA) Drops 32% After Trial Results Disappoin - GuruFocus
Vera Therapeutics (VERA) Stock Plummets Over 29% in Major Sell-Off - Daily Chhattisgarh News
Biotech Stock Vera Is Slumping After Monster Gain - Barron's
Vera Therapeutics stock sinks following competitor’s successful trial By Investing.com - Investing.com Nigeria
Vera Therapeutics stock sinks following competitor’s successful trial - Investing.com Australia
Vera stock drops as Otsuka bests with IgAN drug (VERA:NASDAQ) - Seeking Alpha
Bank of America Corp DE Sells 106,673 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Research Analysts Offer Predictions for VERA FY2027 Earnings - Defense World
IgA Nephropathy Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approval, Treatment Market, Revenue, Statistics, Therapies, and Companies by DelveInsight - The Globe and Mail
Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com
Scotiabank Increases the Price Target for Vera Therapeutics by $10 - MSN
FY2025 EPS Forecast for Vera Therapeutics Reduced by Analyst - Defense World
(VERA) Trading Advice - news.stocktradersdaily.com
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40 - MSN
Clinical-Stage Biotech Vera Therapeutics Joins Elite Goldman Sachs Healthcare Conference Lineup - Stock Titan
Latham & Watkins Advises Vera Therapeutics in US$500 Million Credit Facility With Oxford Finance - Latham & Watkins LLP
Vera Therapeutics Atacicept: Promising Step In IgAN, But Crowded Road Ahead (Rating Downgrade) - Seeking Alpha
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans - GlobeNewswire
Equities Analysts Set Expectations for VERA Q2 Earnings - Defense World
Vera Therapeutics (NASDAQ:VERA) Sees Large Volume Increase on Analyst Upgrade - Defense World
Vera Therapeutics eyes half billion dollars after kidney drug study - The Business Journals
Vera Therapeutics (VERA) Price Target Increased Amid Positive Tr - GuruFocus
Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40 By Stocktwits - Investing.com India
Vera Therapeutics (VERA) Secures $500 Million Credit Facility - GuruFocus
Vera Therapeutics (VERA) Sees Price Target Boost Following Positive Trial Results | VERA Stock News - GuruFocus
Vera Therapeutics Secures $500M Loan Agreement - TipRanks
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 ... - Bluefield Daily Telegraph
Vera Therapeutics Lands Massive $500M Financing Deal as FDA Filing for Kidney Drug Approaches - Stock Titan
Two Sigma Investments LP Sells 7,102 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics (NASDAQ:VERA) PT Set at $65.00 by Scotiabank - Defense World
Vera Therapeutics (NASDAQ:VERA) Given New $85.00 Price Target at HC Wainwright - Defense World
Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday - Yahoo Finance
These 10 Stocks Blew Past Expectations - Insider Monkey
Vera Therapeutics (NASDAQ:VERA) Shares Gap Up After Analyst Upgrade - Defense World
Vera Therapeutics: Primary endpoint was met in ORIGIN Phase 3 trial of atacicept - TipRanks
H.C. Wainwright ups Vera Therapeutics target on ‘home run’ data - TipRanks
Vera Therapeutics Inc Azioni (VERA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vera Therapeutics Inc Azioni (VERA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ENRIGHT PATRICK G | Director |
Jun 24 '25 |
Buy |
22.35 |
40,607 |
907,635 |
3,596,593 |
| Fordyce Marshall | PRESIDENT AND CEO |
Feb 21 '25 |
Sale |
27.89 |
10,613 |
296,032 |
213,740 |
| Fordyce Marshall | PRESIDENT AND CEO |
Feb 26 '25 |
Sale |
27.65 |
9,075 |
250,882 |
204,665 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):